Coldstream Laboratories partners with the National Cancer Institute for developing parental dosage forms for cancer drugs.
Coldstream Laboratories, a provider of sterile drug-product development and manufacturing services, has been awarded a five-year contract with the National Cancer Institute (NCI), with the objective of developing and producing pharmaceutically acceptable parenteral dosage forms of cancer drugs for human use. Certain lead agents selected by the NCI will be assigned for development and production as parenteral products.
Coldstream Laboratories, based in Lexington, Kentucky, is a privately held CMO. It was formed in 2007 as a spin off from the University of Kentucky's Center for Pharmaceutical Sciences and Technology.
